Literature DB >> 19734632

Surgical resection after TNFerade therapy for locally advanced pancreatic cancer.

Manpreet K Chadha1, Alan Litwin, Charles Levea, Renuka Iyer, Gary Yang, Milind Javle, John F Gibbs.   

Abstract

CONTEXT: Treatment of pancreatic cancer remains a major oncological challenge and survival is dismal. Most patients, present with advanced disease at diagnosis and are not candidates for curative resection. Preoperative chemoradiation may downstage and improve survival in locally advanced pancreatic cancer. This has prompted investigators to look for novel neoadjuvant therapies. Gene therapy for pancreatic cancer is a novel investigational approach that may have promise. TNFerade is a replication deficient adenovirus vector carrying the human tumor necrosis factor (TNF)-alpha gene regulated under control of a radiation-inducible gene promoter. Transfection of tumor cells with TNFerade maximizes the antitumor effect of TNF-alpha under influence of radiation leading to synergistic effects in preclinical studies. CASE REPORT: We describe a case of locally advanced unresectable pancreatic cancer treated with a novel multimodal approach utilizing gene therapy with TNFerade and concurrent chemoradiation that was followed by successful surgical resection.
CONCLUSION: Neoadjuvant TNFerade based chemoradiation therapy may be a useful adjunct to treatment of locally advanced pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734632

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  4 in total

Review 1.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Discovering the route from inflammation to pancreatic cancer.

Authors:  N Momi; S Kaur; S R Krishn; S K Batra
Journal:  Minerva Gastroenterol Dietol       Date:  2012-12

3.  Long-Term Relapse-Free Survival by Interdisciplinary Collaboration in a Patient with Metastatic Pancreatic Cancer (UICC IV).

Authors:  Sandra Roehrig; Axel Wein; Heinz Albrecht; Gudrun Maennlein; Kerstin Wolff; Dane Muskoski; Kerstin Amann; Rolf Janka; Werner Hohenberger; Eckhart G Hahn; Jürgen Siebler; Markus F Neurath; Frank Boxberger
Journal:  Case Rep Oncol       Date:  2011-08-24

4.  Pancreatic cancer gene therapy: from molecular targets to delivery systems.

Authors:  Cristina Fillat; Anabel Jose; Xavier Bofill-Deros; Ana Mato-Berciano; Maria Victoria Maliandi; Luciano Sobrevals
Journal:  Cancers (Basel)       Date:  2011-01-18       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.